SkinCeuticals

TRIPLE LIPID RESTORE 2:4:2 + RETINOIDS

INTRODUCTION

Topical retinoid therapy is a long-established course of treatment in dermatology, most widely known for its effectiveness in managing skin aging and acne. However, mild to moderate cutaneous side effects due to topical retinoid use, such as peeling, erythema, and subjective irritation, are experienced by a majority of patients. In order to minimize the adverse effects related to retinoid therapy, it is generally recommended that a retinoid treatment regimen consist of application on alternate nights for the first 2 weeks of use, at minimum, or until deemed tolerable.

OBJECTIVE

The goal of the present study was to evaluate the clinical effects of Triple Lipid Restore 2:4:2 in improving the tolerance of 0.025% topical retinoid therapy.

CLINICAL METHODOLOGY

A 4-week, single-center, double-blind, randomized, split-face clinical study was conducted on 17 subjects to evaluate Triple Lipid Restore 2:4:2 in improving tolerance of 0.025% tretinoin therapy.

Tolerability evaluations were conducted at baseline, weeks 4, 8, and 12. Cutaneous tolerability was evaluated by assessing subjective and objective irritation of the treatment area. Clinically-graded objective irritation parameters included erythema, dryness, scaling, and edema. In addition, subjects self-assessed burning, stinging, itching, tightness, and tingling. Tretinoin treatment step-up assessments were conducted at week 1 and week 2.

Inclusion Criteria

- Females aged 38-64
- Fitzpatrick I-V
- Self-reported retinoid averse (individuals opposed to using a retinoid due to anticipated intolerance and/or individuals who have previously used a retinoid and experienced intolerance)

PROTOCOL

Triple Lipid Restore 2:4:2 and a comparative lotion were applied to the face in a split-face, randomized manner. Subjects were instructed to apply topical 0.025% tretinoin (Rouses Point Pharmaceuticals) to their whole face at home every other evening for 1 week. Based on the subjects' tolerability, topical 0.025% tretinoin application was increased to every evening at the week 1 or week 2 visit.

The support regimen was limited to a basic cleanser (Gentle Cleanser) and sunscreen (Physical Fusion SPF 50).

RESULTS

The results from this study indicated that Triple Lipid Restore 2:4:2 was effective in improving the tolerance of retinoid therapy.

Triple Lipid Restore 2:4:2 allowed for all 17 subjects to achieve a 1 week decrease in 0.025% tretinoin pre-conditioning, shortening the current standard treatment of care by 1 week.

In addition, a significant improvement in dryness was observed with Triple Lipid Restore 2:4:2 at week 2, compared to baseline. (Graph 1, Figure 1)

At week 4, the subjects reported that the half of the face treated with Triple Lipid Restore 2:4:2 was significantly more comfortable than the half of the face treated with the comparative lotion. (Graph 2)

CLINICAL STUDY RESULTS

Graph 1: Significant Improvement In Dryness



Graph 2: Preferred Aesthetic



Figure 1: Images - Dryness Parameter



Average results

CONCLUSION

Triple Lipid Restore 2:4:2 improved tolerance of 0.025% topical retinoid therapy.

Clinical studies demonstrated:

- decreased tretinoin pre-conditioning period
- significant improvement in cutaneous tolerability
- significant aesthetic preference versus comparative lotion